The 16 most recent market catalysts affecting $DOCS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Equal-Weight on Doximity, Raises Price Target to $27
Barclays analyst Glen Santangelo maintained an 'Equal-Weight' rating on Doximity but raised the price target from $20 to $27. This indicates that while the analyst sees more upside…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
Doximity shares are trading higher after Truist Securities raised its price target on the stock from $19 to $24.
The Truist Securities price target increase from $19 to $24 for Doximity (DOCS) is a significant positive catalyst. Analyst upgrades from well-known firms often act as a strong sig…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Hold on Doximity, Raises Price Target to $24
Truist Securities analyst Jailendra Singh maintained a 'Hold' rating on Doximity (DOCS) while raising the price target from $19 to $24. This action suggests that while the analyst …
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 75
Doximity shares are trading lower after Wells Fargo downgraded the stock from Equal-Weight to Underweight rating and maintained the price target at $18.
The downgrade from Wells Fargo is a significant corporate catalyst for Doximity. While the price target remained unchanged, the shift to an 'Underweight' rating suggests a belief t…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 65
Wells Fargo Downgrades Doximity to Underweight, Maintains Price Target to $18
Wells Fargo analyst Stan Berenshteyn downgraded Doximity (DOCS) from 'Equal-Weight' to 'Underweight,' signaling a reduced confidence in the stock's potential. Despite the downgrade…
Aug 7, 2026
Macro/Central Bank
Bearish
Impact 85
Nasdaq Gains Over 300 Points; US Employers Cut 23,000 Jobs In July
The core of this filing is the unexpected contraction in US nonfarm payrolls by 23,000 in July, significantly missing consensus estimates. This weakening labor market data, coupled…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 92
Doximity CEO Says AI Is Unlocking A Bigger Market Than Expected
Doximity (DOCS) reported better-than-expected fiscal first-quarter revenue and raised its full-year sales guidance, largely attributing this success to the strong adoption and perf…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Neutral on Doximity, Raises Price Target to $31
JP Morgan analyst Alexei Gogolev maintained a 'Neutral' rating on Doximity (DOCS) but raised the price target from $26 to $31. This action suggests that while the analyst sees some…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Reiterates Overweight on Doximity, Raises Price Target to $47
Piper Sandler analyst Jessica Tassan reaffirmed her 'Overweight' rating on Doximity and raised the price target from $42 to $47. This action signals increased confidence in Doximit…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 85
12 Health Care Stocks Moving In Friday's Pre-Market Session
This filing highlights the immediate market reaction to recent earnings reports for a dozen healthcare companies. Doximity (DOCS) saw a massive 85.1% surge after its Q1 earnings, i…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 78
Doximity shares are trading higher after the company reported better-than-expected Q1 sales results and raised its FY27 sales guidance above estimates.
This headline is a significant corporate catalyst for Doximity (DOCS). Exceeding Q1 sales expectations and, more importantly, raising long-term guidance (FY27) signals strong under…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
12 Health Care Stocks Moving In Thursday's After-Market Session
The filing details the after-market performance of 12 healthcare stocks, with 6 experiencing significant gains and 6 experiencing substantial losses. The primary catalyst for these…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Doximity shares are trading higher after the company reported better-than-expected Q1 sales results and raised its FY27 sales guidance above estimates.
This headline represents a significant positive corporate catalyst for Doximity (DOCS). Exceeding Q1 sales expectations and, more importantly, raising long-term guidance (FY27) ind…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Doximity Raises FY2027 Sales Guidance from $664.000M-$676.000M to $671.000M-$681.000M vs $670.288M Est
Doximity (DOCS) has filed an 8-K to announce an upward revision to its fiscal year 2027 sales guidance. The new range of $671 million to $681 million is higher than the previous $6…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 65
Doximity Q1 Adj. EPS $0.29 Misses $0.30 Estimate, Sales $156.618M Beat $151.727M Estimate
This headline indicates a mixed financial performance for Doximity. The EPS miss, even if slight, often triggers a negative initial market reaction as profitability is a key metric…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 65
Doximity Announces Doximity Ask Came Ahead Of Frontier AI Models In Numerous Options Harm Assessment For Risk In Medicine Benchmark
Doximity (DOCS) announced that its Doximity Ask AI platform outperformed leading frontier AI models in the NOHARM benchmark, an independent clinical AI safety evaluation. This is s…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.